Kelzy (Dienogest, Ethinylestradiol | Lactose)

The ethinylestradiol component provides estrogenic activity that suppresses the pituitary release of follicle‑stimulating hormone, while dienogest, a progestogen, blocks luteinizing hormone surge and induces changes in cervical mucus and endometrium. Together they prevent ovulation and create an environment hostile to fertilization and implantation.

The dosing regimen for Kelzy is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily for a 21‑day active tablet sequence followed by a hormone‑free interval, but the exact schedule, tablet strength, and duration should be confirmed with the prescriber.

Kelzy is intended for use only when pregnancy is not desired; it should be discontinued if pregnancy occurs. The product is not recommended for use during pregnancy. Limited data are available for breastfeeding, and the decision to use hormonal contraception while nursing should be made by a qualified clinician based on individual risk‑benefit assessment.

To place an order, submit an enquiry on the Kelzy product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and any necessary import documentation.

Kelzy contains the progestogen dienogest, which has a lower androgenic profile compared with older agents such as levonorgestrel, potentially offering better control of acne and less impact on lipid metabolism. Its estrogen component, ethinylestradiol, is similar to that in many other COCs, providing comparable contraceptive efficacy while differing in side‑effect tolerability.

Kelzy tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Kelzy is taken orally, usually once each day at the same time, with or without food. The typical regimen consists of a series of active tablets followed by a hormone‑free interval, after which a new pack is started. Consistent daily intake is essential to maintain contraceptive effectiveness.

The most serious risks include venous thromboembolism, arterial thrombosis, and severe hypertension, which can be life‑threatening. Additional rare but serious concerns are liver tumors and allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience chest pain, shortness of breath, severe headache, visual changes, or swelling of the legs.

Kelzy is contraindicated in women with a history of thromboembolic disorders, estrogen‑dependent tumors (e.g., breast cancer), uncontrolled hypertension, active liver disease, or known hypersensitivity to any component. It should also be avoided in smokers over 35 years of age and in individuals taking medications that significantly reduce contraceptive efficacy.